Pyrotinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) targeting HER1, HER2, and HER4, which has been proven effective in the PHEOBE9 and PHENIX10 trials, and approved for the treatment of HER2-positive ABC in China11. Here, EGFR is linked to aneurysmal bone cyst.